(Q51016808)

27 March 2018

title

Effect of CYP2D6 polymorphisms on breast cancer recurrence. (English)

1 reference

27 March 2018

Ana Maria Gonzalez-Angulo

author

11

object named as

Ana M Gonzalez-Angulo

1 reference

27 March 2018

author name string

Phuong K Morrow

1

1 reference

27 March 2018

Ruben Serna

2

1 reference

27 March 2018

Kristine Broglio

3

1 reference

27 March 2018

Lajos Pusztai

4

1 reference

27 March 2018

D Michelle Nikoloff

5

1 reference

27 March 2018

Grantland R Hillman

6

1 reference

27 March 2018

Marcel Fontecha

7

1 reference

27 March 2018

Rui Li

8

1 reference

27 March 2018

Laura Michaud

9

1 reference

27 March 2018

Gabriel Hortobagyi

10

1 reference

27 March 2018

language of work or name

English

0 references

publication date

5 August 2011

1 reference

27 March 2018

published in

Cancer

1 reference

27 March 2018

volume

118

1 reference

27 March 2018

issue

5

1 reference

27 March 2018

page(s)

1221-1227

1 reference

27 March 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Genes and the response to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

inferred from DOI database lookup

7 January 2021

based on heuristic

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26407

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26407

1 reference

27 March 2018

1 reference

27 March 2018